CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.83: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
531.30MUSDvs all stocks (USD)
Revenue (TTM)
71.10MUSDvs all stocks (USD)
Profit Margin
-8.98%vs Biotechnology peers
Beta
1.08xvs all stocks
52-Week Change
46.90%vs all stocks
Market Capitalization
531.30MUSDvs all stocks (USD)
Enterprise Value
201.97MUSDvs all stocks (USD)
Forward P/E
-12.74xvs Biotechnology peers
Price to Sales (TTM)
7.47xvs Biotechnology peers
Price to Book (MRQ)
2.15xvs Biotechnology peers
Enterprise to Revenue
2.84xvs Biotechnology peers
Enterprise to EBITDA
-15.04xvs Biotechnology peers
Profit Margin
-8.98%vs Biotechnology peers
Operating Margin
-138.44%vs Biotechnology peers
Return on Assets (TTM)
-5.06%vs Biotechnology peers
Return on Equity (TTM)
-5.66%vs Biotechnology peers
Revenue (TTM)
71.10MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.24USDUpdated Jul 18, 2026Quarterly Revenue Growth
-12.80%vs Biotechnology peers
Gross Profit (TTM)
6.24MUSDvs all stocks (USD)
EBITDA (TTM)
-13.43MUSDvs all stocks (USD)
Net Income (TTM)
-6.38MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.80%vs Biotechnology peers
Operating Cash Flow (TTM)
-39.75MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.56MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
72.30MUSDFY2025 · Dec 31, 2025Operating Income
-12.12MUSDvs all stocks (USD)
Pre-tax Income
-6.12MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-6.12MUSDFY2025 · Dec 31, 2025EBIT
-12.12MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-11.99MUSDFY2025 · Dec 31, 2025Research & Development
64.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
19.61MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5500USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
11.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-6.12MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-37.70MUSDFY2025 · Dec 31, 2025Free Cash Flow
-37.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
58.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-6.12MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
129.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
851.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-974.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
586.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.85MUSDFY2025 · Dec 31, 2025Capital Expenditures
-66.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-229.83MUSDFY2025 · Dec 31, 2025Sale of Investments
116.43MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-113.47MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
168.31MUSDFY2025 · Dec 31, 2025Shares Outstanding
15.89MSharesUpdated Jul 18, 2026Float Shares
8.80MSharesUpdated Jul 18, 2026Shares Short
2.41MSharesUpdated Jul 18, 2026Short Ratio
8.54daysvs all stocks
Short % of Shares Outstanding
16.32%vs all stocks
% Held by Insiders
28.42%vs all stocks
% Held by Institutions
48.46%vs all stocks
Total Cash (MRQ)
226.60MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
14.26USDUpdated Jul 18, 2026Total Debt (MRQ)
2.49MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0125xvs Biotechnology peers
Current Ratio (MRQ)
6.65xvs Biotechnology peers
Book Value per Share (MRQ)
12.50USDUpdated Jul 18, 2026Total Assets
257.59MUSDvs all stocks (USD)
Total Current Assets
254.55MUSDFY2025 · Dec 31, 2025Total Liabilities
50.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.04MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
48.78MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
58.45MUSDFY2025 · Dec 31, 2025Other Short-term Investments
189.66MUSDFY2025 · Dec 31, 2025Accounts Receivable
974.00KUSDFY2025 · Dec 31, 2025Accounts Payable
1.17MUSDFY2025 · Dec 31, 2025Short-term Debt
569.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
36.90MUSDFY2025 · Dec 31, 2025Long-term Debt
2.06MUSDFY2025 · Dec 31, 2025Common Stock (Book)
16.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-832.05MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
206.75MUSDvs all stocks (USD)
52-Week Low
16.90USDUpdated Jul 18, 202652-Week High
39.71USDUpdated Jul 18, 202652-Week Change
46.90%vs all stocks
Beta
1.08xvs all stocks
50-Day MA
26.68USDUpdated Jul 18, 2026200-Day MA
29.22USDUpdated Jul 18, 2026Avg 10-Day Volume
180.69KSharesUpdated Jul 18, 2026Avg 30-Day Volume
248.55KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
0.0800USDUpdated Jul 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.83: safe zoneNotable
Altman Z-Score: 2.83
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC